6.025

2.43% -0.15

Precipio Inc (PRPO)

Overview News Price History Discussions Forecast Stock Split

Precipio Inc stock is currently priced at $6.025, with a 24-hour trading volume of 9,309. It has seen a -2.43% decreased in the last 24 hours and a -0.97% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $6.06 pivot point. If it approaches the $5.82 support level, significant changes may occur.

Previous Close:

$6.175

Open:

$6.214

24h Volume:

9,309

Market Cap:

$8.62M

Revenue:

$15.20M

Net Income/Loss:

$-5.85M

P/E Ratio:

-0.6549

EPS:

-9.2

Net Cash Flow:

$-3.69M

1W Performance:

-2.82%

1M Performance:

-0.97%

6M Performance:

-28.74%

1Y Performance:

+937.01%

1D Range:

$5.80

$6.214

52W Range:

$0.2505

$8.99

Precipio Inc Stock (PRPO) Company Profile

Name

Precipio Inc

Sector

Healthcare (1191)

Industry

Diagnostics & Research (66)

Phone

203 787 7888

Address

4 Science Park, 3rd Floor, New Haven, CT

Employee

Twitter

@precipiodx

Next Earnings Date

2024-05-15

Latest SEC Filings

PRPO's Discussions on Twitter

Precipio Inc Stock (PRPO) Latest News

Precipio Announces Year end 2023 Shareholder Update Call

GlobeNewswire Inc.

Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY

GlobeNewswire Inc.

Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for Cancer

GlobeNewswire Inc.

Precipio’s Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter

GlobeNewswire Inc.

Precipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan

GlobeNewswire Inc.

Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024

GlobeNewswire Inc.

Precipio Inc Stock (PRPO) Financials Data

Precipio Inc (PRPO) Revenue 2024

PRPO reported a revenue (TTM) of $15.20 million for the quarter ending December 31, 2023, a +61.46% rise year-over-year.

Precipio Inc (PRPO) Net Income 2024

PRPO net income (TTM) was -$5.85 million for the quarter ending December 31, 2023, a +52.04% increase year-over-year.

Precipio Inc (PRPO) Cash Flow 2024

PRPO recorded a free cash flow (TTM) of -$3.69 million for the quarter ending December 31, 2023, a +53.93% increase year-over-year.

Precipio Inc (PRPO) Earnings per Share 2024

PRPO earnings per share (TTM) was -$4.56 for the quarter ending December 31, 2023, a +56.98% growth year-over-year.

Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.